Want to see DCOY full AI Analyst Report?
DCOY Stock Chart & Stats
$5.81
-$0.06(-3.48%)
At close: 4:00 PM EST
$5.81
-$0.06(-3.48%)
Day’s Range― - ―
52-Week Range$3.51 - $106.20
Previous CloseN/A
VolumeN/A
Average Volume (3M)356.88K
Market Cap
$2.43M
Enterprise Value-$4.66M
Total Cash (Recent Filing)$7.82M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.12
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding590,185
10 Day Avg. Volume434,140
30 Day Avg. Volume356,875
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.64
Price to Sales (P/S)0.00
P/FCF Ratio-0.78
Enterprise Value/Market Cap-1.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.55
Enterprise Value/Ebitda0.36
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Zero Debt (low Leverage)Having no recorded debt materially reduces fixed financing obligations for a clinical-stage biotech. Low leverage preserves financial flexibility to prioritize R&D and manage timing of capital raises, lowering insolvency risk and enabling management to focus cash on advancing clinical programs over the coming months.
PIPE Financing With Milestone UpsideA June 2026 PIPE provides immediate non-dilutive-ish capital flow and conditional milestone financing, directly funding advancement of the lead antiviral into trials. Structurally, this extends the company’s runway tied to clinical progress and signals institutional investor support for program continuation.
Material Reduction In Historical LossesNet losses have narrowed materially from 2022 levels, reflecting tighter cost control or scaled operations. For a pre-revenue firm this implies improved capital efficiency: each dollar now funds a larger share of development activities, which can extend runway and improve the odds of reaching near-term milestones without immediate follow-on raises.
Bears Say
Pre-revenue With Persistent Cash BurnThe company generates no product revenue while burning cash from operations. Negative operating and free cash flow tied to net losses means spending is real, not mostly non-cash, requiring recurring external financing to continue clinical development and increasing execution risk if capital markets tighten.
Eroding Shareholders' EquitySteady declines in equity reflect cumulative losses and shrink the balance-sheet cushion. A thinner equity base reduces the firm’s capacity to absorb adverse results, increases reliance on external capital, and can force dilutive financings or constrain strategic options during the next stages of clinical development.
Milestone-linked Financing Creates Dilution And Funding RiskRelying on milestone-triggered warrants concentrates funding on positive clinical outcomes: if milestones succeed dilution will occur via warrant exercise; if they fail, anticipated capital may not materialize. That binary funding model raises long-term execution and dilution risk for sustaining programs to later-stage trials.
Decoy Therapeutics News
DCOY FAQ
What was Decoy Therapeutics’s price range in the past 12 months?
Decoy Therapeutics lowest stock price was $3.51 and its highest was $106.20 in the past 12 months.
What is Decoy Therapeutics’s market cap?
Decoy Therapeutics’s market cap is $2.43M.
When is Decoy Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Decoy Therapeutics’s earnings last quarter?
Currently, no data Available
Is Decoy Therapeutics overvalued?
According to Wall Street analysts Decoy Therapeutics’s price is currently Overvalued.
Does Decoy Therapeutics pay dividends?
Decoy Therapeutics does not currently pay dividends.
What is Decoy Therapeutics’s EPS estimate?
Decoy Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Decoy Therapeutics have?
Decoy Therapeutics has 590,185 shares outstanding.
What happened to Decoy Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Decoy Therapeutics?
Currently, no hedge funds are holding shares in DCOY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Decoy Therapeutics
Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.